The molecular pathogenesis of primary mediastinal large B-cell lymphoma
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The molecular pathogenesis of primary mediastinal large B-cell lymphoma
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 10, Pages 2659-2669
Publisher
American Society of Hematology
Online
2011-06-24
DOI
10.1182/blood-2011-05-326538
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma
- (2011) L. Giulino et al. BLOOD
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
- (2011) E. Campo et al. BLOOD
- Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma
- (2011) F. C. Eberle et al. HAEMATOLOGICA
- Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
- (2011) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Inactivating mutations of acetyltransferase genes in B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
- (2010) M. Rieger et al. ANNALS OF ONCOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma
- (2010) M. A. Milhollen et al. BLOOD
- Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens
- (2010) B. Falini et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cooperative Epigenetic Modulation by Cancer Amplicon Genes
- (2010) Lixin Rui et al. CANCER CELL
- Dynamic Mathematical Modeling of IL13-Induced Signaling in Hodgkin and Primary Mediastinal B-Cell Lymphoma Allows Prediction of Therapeutic Targets
- (2010) V. Raia et al. CANCER RESEARCH
- Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children
- (2010) I. Oschlies et al. HAEMATOLOGICA
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma
- (2009) O. Ritz et al. BLOOD
- STAT6 in PMBL: pathogenic or passenger?
- (2009) D. A. Frank BLOOD
- The NF- B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas
- (2009) U. Novak et al. BLOOD
- TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas
- (2009) K. Honma et al. BLOOD
- Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities
- (2009) A. Mottok et al. BLOOD
- Interleukin-13 stimulation of the mediastinal B-cell lymphoma cell line Karpas-1106P induces a phenotype resembling the Hodgkin lymphoma cell line L1236
- (2009) Erik Andersson et al. EXPERIMENTAL HEMATOLOGY
- CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression
- (2009) L. M. Rimsza et al. HAEMATOLOGICA
- TNFAIP3(A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
- (2009) Roland Schmitz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma
- (2009) E Chanudet et al. LEUKEMIA
- JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
- (2009) Mark A. Dawson et al. NATURE
- Frequent inactivation of A20 in B-cell lymphomas
- (2009) Motohiro Kato et al. NATURE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
- (2008) D. Buglio et al. BLOOD
- PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
- (2008) R. Yamamoto et al. BLOOD
- Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
- (2008) L. M. Rimsza et al. BLOOD
- Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
- (2008) A. Tzankov et al. HAEMATOLOGICA
- Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience
- (2008) José Rodríguez et al. HEMATOLOGICAL ONCOLOGY
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started